Piramal
A diversified conglomerate with operational presence in pharma, financial services, information management and real estate.
- Healthcare
- Finance
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $64.0m | Post IPO Debt |
| Total Funding | 000k | ||
| INR | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 8 % | (65 %) | 94 % | (4 %) | (33 %) | 20 % | 19 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 58 % | 96 % | 57 % | 89 % | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 14 % | 300 % | (18 %) | 5 % | 23 % | 25 % | 26 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1 % | - | - | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Piramal Group is a global business conglomerate with diverse interests spanning pharmaceuticals, financial services, and real estate. The company serves a wide range of clients including healthcare providers, financial institutions, and real estate developers. Operating in over 100 markets worldwide, Piramal Group has established a strong presence with offices in more than 30 countries and a workforce of over 10,000 employees from 21 diverse nationalities.
In the pharmaceutical sector, Piramal Group focuses on critical care, injectable anesthesia, and pain management products. The company has expanded its product portfolio through strategic acquisitions, such as Janssen's Injectable Anaesthesia and Pain Management products and Ash Stevens Inc., a US-based Contract and Drug Manufacturing Organization (CDMO) for High Potency APIs (HPAPIs).
In financial services, Piramal Group engages in distressed debt investing in India through a partnership with Bain Capital Credit. This venture aims to capitalize on opportunities in the distressed asset space, providing financial solutions to businesses in need.
Piramal Realty, the real estate arm of the group, has ventured into commercial real estate, focusing on creating high-quality, sustainable developments that enhance the urban landscape.
The company's business model is built on the foundation of trusteeship, aiming to create value for all stakeholders, including customers, community, employees, partners, and shareholders. Piramal Group generates revenue through the sale of pharmaceutical products, financial services, and real estate developments.
Keywords: pharmaceuticals, financial services, real estate, critical care, injectable anesthesia, pain management, distressed debt, CDMO, high potency APIs, sustainable developments.
Tech stack
